Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia

Brian Mejak, Carmen Giacomuzzi, Eileen Heller, Xiaomang You, Ross Ungerleider, Irving Shen, Lynn Boshkov

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

We report a post-Norwood Stage I patient requiring ECMO support using Argatroban as an anticoagulant following diagnosis of heparin-induced thrombocytopenia (HIT). A 2.6 kg female was born with hypoplastic left heart syndrome and underwent a Norwood Stage I operation on day 4 of life. The patient weaned off cardiopulmonary bypass with no complications and was routinely placed on a ventricular assist device (VAD) for 3 days. Heparin was infused at a rate of 16-32 IU/kg/h to maintain an ACT of 160-180 seconds. Two days after VAD termination, the patient was placed on continuous veno-veno hemofiltration (CVVH). Shortly after CVVH, the patient was diagnosed with HIT and placed on an Argatroban infusion. Five days later, a VAD and subsequent ECMO was used because of decreasing left ventricular function, gross body edema, and poor renal function. This case report summarizes the use of Argatroban during VAD and ECMO support for a patient diagnosed with HIT.

Original languageEnglish (US)
Pages (from-to)178-181
Number of pages4
JournalJournal of Extra-Corporeal Technology
Volume36
Issue number2
StatePublished - Jun 2004

Fingerprint

Heart-Assist Devices
Thrombocytopenia
Heparin
Hemofiltration
Hypoplastic Left Heart Syndrome
Cardiopulmonary Bypass
Left Ventricular Function
Anticoagulants
Edema
argatroban
Kidney

Keywords

  • Anticoagulant
  • Argatroban
  • Extracorporeal membrane oxygenation

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Mejak, B., Giacomuzzi, C., Heller, E., You, X., Ungerleider, R., Shen, I., & Boshkov, L. (2004). Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia. Journal of Extra-Corporeal Technology, 36(2), 178-181.

Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia. / Mejak, Brian; Giacomuzzi, Carmen; Heller, Eileen; You, Xiaomang; Ungerleider, Ross; Shen, Irving; Boshkov, Lynn.

In: Journal of Extra-Corporeal Technology, Vol. 36, No. 2, 06.2004, p. 178-181.

Research output: Contribution to journalArticle

Mejak, B, Giacomuzzi, C, Heller, E, You, X, Ungerleider, R, Shen, I & Boshkov, L 2004, 'Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia', Journal of Extra-Corporeal Technology, vol. 36, no. 2, pp. 178-181.
Mejak, Brian ; Giacomuzzi, Carmen ; Heller, Eileen ; You, Xiaomang ; Ungerleider, Ross ; Shen, Irving ; Boshkov, Lynn. / Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia. In: Journal of Extra-Corporeal Technology. 2004 ; Vol. 36, No. 2. pp. 178-181.
@article{a9a2cf2ffad34ae4ac62f86f745dacf0,
title = "Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia",
abstract = "We report a post-Norwood Stage I patient requiring ECMO support using Argatroban as an anticoagulant following diagnosis of heparin-induced thrombocytopenia (HIT). A 2.6 kg female was born with hypoplastic left heart syndrome and underwent a Norwood Stage I operation on day 4 of life. The patient weaned off cardiopulmonary bypass with no complications and was routinely placed on a ventricular assist device (VAD) for 3 days. Heparin was infused at a rate of 16-32 IU/kg/h to maintain an ACT of 160-180 seconds. Two days after VAD termination, the patient was placed on continuous veno-veno hemofiltration (CVVH). Shortly after CVVH, the patient was diagnosed with HIT and placed on an Argatroban infusion. Five days later, a VAD and subsequent ECMO was used because of decreasing left ventricular function, gross body edema, and poor renal function. This case report summarizes the use of Argatroban during VAD and ECMO support for a patient diagnosed with HIT.",
keywords = "Anticoagulant, Argatroban, Extracorporeal membrane oxygenation",
author = "Brian Mejak and Carmen Giacomuzzi and Eileen Heller and Xiaomang You and Ross Ungerleider and Irving Shen and Lynn Boshkov",
year = "2004",
month = "6",
language = "English (US)",
volume = "36",
pages = "178--181",
journal = "Journal of Extra-Corporeal Technology",
issn = "0022-1058",
publisher = "American Society of Extra-Corporeal Technology",
number = "2",

}

TY - JOUR

T1 - Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia

AU - Mejak, Brian

AU - Giacomuzzi, Carmen

AU - Heller, Eileen

AU - You, Xiaomang

AU - Ungerleider, Ross

AU - Shen, Irving

AU - Boshkov, Lynn

PY - 2004/6

Y1 - 2004/6

N2 - We report a post-Norwood Stage I patient requiring ECMO support using Argatroban as an anticoagulant following diagnosis of heparin-induced thrombocytopenia (HIT). A 2.6 kg female was born with hypoplastic left heart syndrome and underwent a Norwood Stage I operation on day 4 of life. The patient weaned off cardiopulmonary bypass with no complications and was routinely placed on a ventricular assist device (VAD) for 3 days. Heparin was infused at a rate of 16-32 IU/kg/h to maintain an ACT of 160-180 seconds. Two days after VAD termination, the patient was placed on continuous veno-veno hemofiltration (CVVH). Shortly after CVVH, the patient was diagnosed with HIT and placed on an Argatroban infusion. Five days later, a VAD and subsequent ECMO was used because of decreasing left ventricular function, gross body edema, and poor renal function. This case report summarizes the use of Argatroban during VAD and ECMO support for a patient diagnosed with HIT.

AB - We report a post-Norwood Stage I patient requiring ECMO support using Argatroban as an anticoagulant following diagnosis of heparin-induced thrombocytopenia (HIT). A 2.6 kg female was born with hypoplastic left heart syndrome and underwent a Norwood Stage I operation on day 4 of life. The patient weaned off cardiopulmonary bypass with no complications and was routinely placed on a ventricular assist device (VAD) for 3 days. Heparin was infused at a rate of 16-32 IU/kg/h to maintain an ACT of 160-180 seconds. Two days after VAD termination, the patient was placed on continuous veno-veno hemofiltration (CVVH). Shortly after CVVH, the patient was diagnosed with HIT and placed on an Argatroban infusion. Five days later, a VAD and subsequent ECMO was used because of decreasing left ventricular function, gross body edema, and poor renal function. This case report summarizes the use of Argatroban during VAD and ECMO support for a patient diagnosed with HIT.

KW - Anticoagulant

KW - Argatroban

KW - Extracorporeal membrane oxygenation

UR - http://www.scopus.com/inward/record.url?scp=3142705748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142705748&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 178

EP - 181

JO - Journal of Extra-Corporeal Technology

JF - Journal of Extra-Corporeal Technology

SN - 0022-1058

IS - 2

ER -